fda2WASHINGTON, D.C. (5/15/13) - The U.S. Food and Drug Administration today approved Xofigo (radium Ra 223 dichloride) to treat men with symptomatic late-stage (metastatic) castration-resistant prostate cancer that has spread to bones but not to other organs. It is intended for men whose cancer has spread after receiving medical or surgical therapy to lower testosterone.

Prostate cancer forms in a gland in the male reproductive system found below the bladder and in front of the rectum. The male sex hormone testosterone stimulates the prostate tumors to grow. According to the National Cancer Institute, an estimated 238,590 men will be diagnosed with prostate cancer and 29,720 will die from the disease in 2013.

Xofigo is being approved more than three months ahead of the product’s prescription drug user fee goal date of Aug. 14, 2013, the date the agency was scheduled to complete review of the drug application. The FDA reviewed Xofigo under the agency’s priority review program, which provides for an expedited review of drugs that appear to provide safe and effective therapy when no satisfactory alternative therapy exists, or offer significant improvement compared to marketed products.

“Xofigo binds with minerals in the bone to deliver radiation directly to bone tumors, limiting the damage to the surrounding normal tissues,” said Richard Pazdur, M.D., director of the Office of Hematology and Oncology Products in the FDA’s Center for Drug Evaluation and Research. “Xofigo is the second prostate cancer drug approved by the FDA in the past year that demonstrates an ability to extend the survival of men with metastatic prostate cancer.”

In August 2012, the FDA approved Xtandi to treat men with metastatic castration-resistant prostate cancer that has spread or recurred, even with medical or surgical therapy to minimize testosterone. Xtandi is approved for patients who have previously been treated the chemotherapy drug docetaxel.

Xofigo’s safety and effectiveness were evaluated in a single clinical trial of 809 men with symptomatic castration-resistant prostate cancer that spread to bones but not to other organs. Patients were randomly assigned to receive Xofigo or a placebo plus best standard of care.

The study was designed to measure overall survival. Results from a pre-planned interim analysis showed men receiving Xofigo lived a median of 14 months compared to a median of 11.2 months for men receiving placebo. An exploratory updated analysis conducted later in the trial confirmed Xofigo’s ability to extend overall survival.

The most common side effects reported during clinical trials in men receiving Xofigo were nausea, diarrhea, vomiting and swelling of the leg, ankle or foot. The most common abnormalities detected during blood testing included low levels of red blood cells (anemia), lymphocytes (lymphocytopenia), white blood cells (leukopenia), platelets (thrombocytopenia) and infection-fighting white blood cells (neutropenia).

Xofigo is marketed by Wayne, N.J.-based Bayer Pharmaceuticals. Xtandi is co-marketed by Astellas Pharma U.S., Inc. of Northbrook, Ill., and Medivation, Inc. of San Francisco, Calif.
 
SurfKY News
Information provided by the United States Food and Drug Administration

LIKE SurfKY on Facebook - Click here to LIKE us now.

© Copyright 2015 SurfKY News Group, Inc. All rights reserved. This material may not be published, broadcast, or rewritten without permission. SurfKY News encourages you to share this story on social media.

In Other News...

Eagles Defeat Marshall County via Mercy Rule

DRAFFENVILLE, Ky. (5/4/15) — Visiting Apollo clubbed 17 hits to beat Marshall County 13-3 in five innings via the… Read More

KMA Announces 'Cell Phones for Soldiers' Drive May 16

WEBSTER COUNTY, Ky. (5/4/15) — The Kentucky Motorcycle Association, District 14 proudly supports Cell Phones for… Read More

Most Read This Week

April 28, 2015 4159

Search for Stolen Vehicle Ends with Woman Charged…

by SurfKY News
April 27, 2015 3496

Online Petition Seeking Re­opening of Shanice…

by Samantha Carver, SurfKY News
April 28, 2015 3343

Man Charged with Stalking Smoke Shop Clerk

by MPD
April 27, 2015 2898

Hopkins County Drug War ― Are We Winning?

by Doreen Dennis, SurfKY News
April 30, 2015 2799

Family Says 'Goodbye' to Dog After It Allegedly…

by Doreen Dennis, SurfKY News

Most Read This Month

April 17, 2015 15534

An Open Letter from an Addict

by Olivia Kirks
April 23, 2015 8481

Man Charged with Sodomy, Incest/Victim under 12

by SurfKY News

Stories Trending Now

May 03, 2015 1403

Two Injured During Two-Vehicle Collision

by SurfKY News
May 04, 2015 1281

Teen Injured During Collision with Police Cruiser

by SurfKY News
May 03, 2015 1085

Faith Baptist Hosts Family Fun Day

by Tammy Holloway, SurfKY News
May 04, 2015 1031

Alleged Littering Leads to Drug Arrest

by SurfKY News
May 04, 2015 817

Three Injured in Two-Vehicle Collision

by SurfKY News
May 03, 2015 735

Dave Says - May 3, 2015

by Dave Ramsey
May 03, 2015 650

2015 Correctional Employees' Week Celebrated…

by Michael Caudill
May 02, 2015 648

Baptist Health Hosts Annual ‘Bike Safety Day’

by Gary Gates, SurfKY News
May 02, 2015 636

Conquering the clutter: Cleanliness with kids is…

by SurfKY News
May 03, 2015 569

Legislator's Log - Week of May 3, 2015

by Brent Yonts